Press Releases Archive

July 14, 2009 - OraVerse® Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009
Feb 27, 2009 - Novalar™ Announces the Launch of OraVerse® the First Dental Anesthesia Reversal Agent
Aug 12, 2008 - Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse® a Local Anesthetic Reversal Agent
May 12, 2008 - Novalar™ Receives FDA Approval for OraVerse®
Dec 18, 2007 - Novalar™ Strengthens Senior Management Team with Key Appointments
Nov 1, 2007 - Novalar™ Raises $30 Million in Series D Financing
Aug 22, 2007 - Novalar™ Appoints Steven J. Semmelmayer to its Board of Directors
July 25, 2007 - Novalar™ announces exclusive license to develop and commercialize antibiotic fiber for root canal therapy.
June 19, 2007 - Novalar™ announces acceptance of OraVerse New Drug Application for filing by FDA.
May 30, 2007 - Novalar™ hires Vice President of Marketing to direct launch of anesthetic reversal agent OraVerse™.
April 10, 2007 - Novalar™ submits New Drug Application for anesthetic reversal agent OraVerse.
March 20, 2007 - Novalar™ presents results from successful studies of anesthetic reversal agent at International Association of Dental Research Annual Meeting.
Nov 15, 2006 - Novalar's™ Positive Phase 2 Pediatric Study Results Support Recent Pivotal Data in Adolescents and Adults.
Oct 3, 2006 - Novalar™ Announces Positive Phase 3 Results for Novel Dental Anesthesia Reversal Agent.
March 16, 2006 - Novalar™ Initiates Pivotal Phase 3 Studies for Novel Dental Anesthesia Reversal Agent.
March 11, 2005 - Novalar Pharmaceuticals™ Raises $27 Million in Series C Financing.
Press Releases